How Smarteeva Automates PMCF Reporting Under EU MDR

What PMCF requires under EU MDR

Post-Market Clinical Follow-Up is defined in EU MDR Annex XIV as a continuous process. It is not a one-time study or a periodic check. It runs across the entire lifecycle of a device on the market.

The core requirement is straightforward: manufacturers must proactively collect and evaluate clinical data to confirm that their device remains safe and performs as intended under real-world conditions. This means tracking outcomes across diverse patient populations, usage environments, and clinical settings that pre-market studies may not have fully represented.

PMCF sits within the broader Post-Market Surveillance (PMS) framework, but it focuses specifically on clinical evidence. Where PMS covers complaints, field actions, and operational data, PMCF zeroes in on clinical outcomes: did the device perform as expected in actual patient care? Are there safety signals that the original clinical evaluation did not capture? Has the benefit-risk profile changed since the device was approved?

The outputs of PMCF feed directly into PSUR (Periodic Safety Update Reports) for higher-risk devices and SSCPs (Summary of Safety and Clinical Performance), creating a reporting chain that regulatory authorities expect to see maintained consistently.

Why PMCF matters beyond compliance

The compliance case for PMCF is obvious: EU MDR requires it, and failing to maintain it puts market authorization at risk. But PMCF data serves purposes that extend well beyond regulatory obligation.

Real-world clinical data collected through PMCF activities informs product development decisions. If a device is performing differently in certain patient populations or clinical environments, that data shapes the next design iteration, labeling update, or instructions for use revision. Manufacturers who treat PMCF as a compliance checkbox miss the product intelligence it generates.

PMCF data also accelerates future regulatory submissions. A manufacturer with robust, well-documented clinical follow-up data has a stronger evidence base for line extensions, new indications, and market expansions. Regulatory bodies view comprehensive PMCF programs as a signal that the manufacturer takes post-market responsibility seriously, which can influence review timelines and approval decisions.

From a risk management perspective, PMCF provides the clinical data layer that complaint tracking alone cannot. A complaint tells you something went wrong. PMCF data tells you whether the device’s clinical performance profile is shifting in ways that require intervention before complaints accumulate.

‍

What PMCF activities look like in practice

The specific PMCF activities a manufacturer runs depend on the device’s risk classification, clinical history, and the gaps identified in the original clinical evaluation.

Common activities include user surveys and questionnaires that collect structured feedback from clinicians using the device, patient registries that track long-term outcomes across defined populations, systematic literature reviews that monitor published evidence related to the device or equivalent devices, adverse event tracking that captures and analyzes safety signals from post-market reporting systems, and in some cases (particularly for high-risk Class III devices or implantables) new clinical investigations designed specifically to answer questions the pre-market data left open.

Lower-risk devices often rely more heavily on existing data: complaint records, literature, and adverse event databases. Higher-risk devices may require active data collection through registries or prospective studies. In all cases, the data must be documented, analyzed, and reported in a format that regulatory authorities can review.

This is where the burden falls hardest on quality and regulatory teams. Each PMCF activity generates data in a different format, from a different source, on a different timeline. Pulling it together into a coherent analysis and a structured report is manual, time-consuming, and repeated for every device in the portfolio and every reporting cycle.

How Smarteeva automates the PMCF workflow

Smarteeva’s approach to PMCF builds on the same infrastructure the platform already uses for PSURs, MIRs, MDRs, and risk management. This means teams are not adopting a separate tool for clinical follow-up. They are extending workflows they already run.

Data aggregation from existing sources

The platform pulls PMCF-relevant data from the systems where it already lives: complaint records, adverse event reports, literature monitoring feeds, clinical study data, and risk management files. Instead of a quality specialist manually searching five different systems and exporting data into a spreadsheet, Smarteeva consolidates the inputs into a single view filtered by device, time period, and data type.

AI-powered analysis

Once the data is aggregated, Smarteeva’s AI layer analyzes it. This includes identifying trends across complaint and adverse event data, flagging clinical signals that may indicate a shift in the device’s benefit-risk profile, and summarizing findings in language that aligns with regulatory reporting requirements. The AI does not replace clinical judgment. It prepares the analytical foundation so PMS staff can focus their review on interpretation and decision-making rather than data assembly.

One-click report generation

With the data aggregated and analyzed, Smarteeva generates the PMCF report. Users configure the report by selecting the device, reporting period, and report type. The system assembles the content (data summaries, trend analyses, risk assessments, literature findings) into a structured document formatted for regulatory submission. The draft goes to PMS staff for review and approval.

Automated distribution

After review, the platform can auto-distribute completed PMCF reports to the appropriate regulatory authorities by email. This closes the loop from data collection through submission without requiring the team to manually package and send the final document.

‍

‍

From data collection to submitted report

The value of automating PMCF is not just speed (though the time savings are significant). It is consistency and coverage.

Manual PMCF processes tend to produce reports that reflect whatever data the analyst had time to find and compile. Under time pressure, data sources get skipped, literature reviews get abbreviated, and the analysis defaults to the most accessible records rather than the most relevant ones. The report meets the minimum requirement, but it does not capture the full clinical picture.

Automated PMCF pulls from every connected data source every time. The scope of the analysis is defined by the configuration, not by how much time the analyst had that week. Literature, complaints, adverse events, risk data, and clinical study results all feed into every report at the same level of completeness.

This also reduces audit risk. When a notified body reviews a PMCF submission, they expect to see evidence that the manufacturer considered all relevant data sources. A report generated from a configured, repeatable workflow with documented data inputs is a stronger submission than one assembled ad hoc from whatever the analyst could pull together.

Smarteeva’s PMCF automation is available now as part of the platform’s post-market surveillance suite. Teams already using Smarteeva for complaints, adverse events, PSURs, or risk management can extend into PMCF without a separate implementation.

‍